Eikon Therapeutics, Inc. — All Filings
46 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0001193125-26-091798 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001193125-26-091787 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001193125-26-091783 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001193125-26-091779 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001193125-26-091771 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001193125-26-091770 | Mar 4, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001193125-26-091767 | Mar 4, 2026 | Mar 2, 2026 |
| SCHEDULE 13G | — | 0001999371-26-003632 | Feb 18, 2026 | — |
| SCHEDULE 13D | — | 0001193125-26-049209 | Feb 12, 2026 | — |
| SCHEDULE 13G | — | 0001104659-26-013367 | Feb 11, 2026 | — |
| 4 | 4 | 0001193125-26-044903 | Feb 10, 2026 | Feb 6, 2026 |
| 4 | 4 | 0001193125-26-043320 | Feb 9, 2026 | Feb 6, 2026 |
| 4 | OWNERSHIP DOCUMENT | 0001104659-26-011662 | Feb 6, 2026 | Feb 4, 2026 |
| 4 | 4 | 0001193125-26-041555 | Feb 6, 2026 | Feb 4, 2026 |
| 4 | 4 | 0001193125-26-041549 | Feb 6, 2026 | Feb 4, 2026 |
| 4 | 4 | 0001193125-26-041544 | Feb 6, 2026 | Feb 4, 2026 |
| S-8 | S-8 | 0001193125-26-041241 | Feb 6, 2026 | — |
| 8-K | 8-K | 0001193125-26-041201 | Feb 6, 2026 | — |
| 424B4 | 424B4 | 0001193125-26-039375 | Feb 5, 2026 | — |
| 3 | 3 | 0001193125-26-038199 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038168 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038167 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038164 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038158 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038147 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038145 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038139 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038137 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038136 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038127 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038125 | Feb 4, 2026 | — |
| 3 | 3 | 0001193125-26-038115 | Feb 4, 2026 | — |
| S-1MEF | S-1MEF | 0001193125-26-037993 | Feb 4, 2026 | — |
| CERT | — | 0001354457-26-000137 | Feb 4, 2026 | — |
| EFFECT | — | 9999999995-26-000406 | Jan 30, 2026 | — |
| 8-A12B | 8-A12B | 0001193125-26-026711 | Jan 28, 2026 | — |
| S-1/A | S-1/A | 0001193125-26-025565 | Jan 28, 2026 | — |
| S-1 | S-1 | 0001193125-26-008888 | Jan 9, 2026 | — |
| DRS/A | — | 0001193125-25-317659 | Dec 12, 2025 | — |
| DRS/A | — | 0001193125-25-220186 | Sep 26, 2025 | — |
| DRS/A | — | 0000950123-25-006156 | Jul 1, 2025 | — |
| DRS | — | 0000950123-25-004458 | May 9, 2025 | — |
| D | — | 0001861123-25-000001 | Feb 28, 2025 | — |
| D | — | 0001861123-23-000001 | Jun 1, 2023 | — |
| D | — | 0001861123-22-000001 | Jan 6, 2022 | — |
| D | — | 0001861123-21-000001 | May 13, 2021 | — |